Companies / Compass Therapeutics, Inc.

Compass Therapeutics, Inc.

Nasdaq: CMPXCIK 1738021BOSTON, MA

Financials

Revenue
Net income$-66.49M
Total debt$0
Cash$35.45M
Diluted EPS
Shares outstanding180.1M

Ownership

180.1M shares outstanding · as of Jul 28, 2026
4.3%Insiders
Ownership
Insiders4.27%7,681,836
10%+ / strategic10.68%19,225,297
Institutions82.11%147,872,070
Public float2.95%5,308,712

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 12

View all →
Insider% of sharesShares
Schuetz Thomas J.CEOCHIEF EXECUTIVE OFFICER · Director
3.67%6,603,336
0.29%525,000
Lerner NeilChief Accounting Officer
0.21%382,500
Anderman JonathanGeneral Counsel
0.09%171,000

Institutional holders 178

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 2, 2026Schuetz Thomas J.
CEO
GrantCommon Stock$1.29M+250K
+3.88%
6,686,800
3.71% of shares
low
Jan 2, 2026Anderman Jonathan
Executive
GrantCommon Stock$775.5K+150K
+714.29%
171,000
0.09% of shares
low
Jan 2, 2026Shin Barry
Executive
GrantCommon Stock$646.3K+125K
+31.25%
525,000
0.29% of shares
low
Jan 2, 2026Lerner Neil
Executive
GrantCommon Stock$323.1K+63K
+19.53%
382,500
0.21% of shares
low
Jan 9, 2026Schuetz Thomas J.
CEO
OtherCommon Stock$250.3K-47K
-0.70%
6,640,023
3.69% of shares
low
Feb 8, 2026Schuetz Thomas J.
CEO
OtherCommon Stock$239.2K-37K
-0.55%
6,603,336
3.67% of shares
low
Jan 2, 2026Ferneau Philip
Director
GrantStock Option (Right to Buy)+90K
90,000
0.05% of shares
low
Jan 2, 2026Sirard Cynthia
Executive
GrantSTOCK OPTION (RIGHT TO BUY)+1.0M
1,000,000
0.56% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
State Street CorporationPassive13G9,953,653
Blackstone Annex Master Fund L.P.Passive13G/A
BlackRock, Inc.Passive13G9,271,644

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
CMPX20454B104